Needham Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $44
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.
Needham analyst Serge Belanger maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Buy and lowers the price target from $46 to $44.